Securities Code: 002393 Securities Abbreviation: Life Science Pharma Announcement No.: 2026-018
Tianjin Life Science & Technology Co., Ltd.
Announcement on Company Directors' 2025 Remuneration and 2026 Remuneration Plan
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
Tianjin Life Science & Technology Co., Ltd. (hereinafter referred to as the "Company" or "this Company") held the fourth meeting of the eighth Board of Directors on March 24, 2026. The meeting deliberated on the "Proposal on the Company Directors' 2025 Remuneration and 2026 Remuneration Plan." As this proposal involves the remuneration of all directors, all directors abstained from voting, and the proposal was directly submitted to the shareholders' meeting for deliberation. The specific details are hereby announced as follows:
I. 2025 Company Directors' Remuneration Situation
In 2025, the Company paid an annual allowance of RMB 80,000 (pre-tax) to independent directors according to the annual allowance standard. For non-independent directors employed by the Company, totaling 2 individuals (excluding directors concurrently serving as senior management), their remuneration was determined based on their specific management positions and performance appraisal results. The total remuneration actually paid in 2025 was RMB 1.5442 million (pre-tax), which included the basic remuneration for 2025 and the performance remuneration for 2024. They did not receive any additional allowances. For non-independent directors not employed by the Company, the Company did not pay any remuneration or allowances. For specific remuneration payment details, please refer to the "Section IV, 3. Directors and Senior Management Remuneration" in the "2025 Annual Report" published by the Company on the Juchao Information Network (www.cninfo.com.cn) on March 25, 2026.